Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy

Herein, we report that genetically programmable fusion cellular vesicles (Fus‐CVs) displaying high‐affinity SIRPα variants and PD‐1 can activate potent antitumor immunity through both innate and adaptive immune effectors. Dual‐blockade of CD47 and PD‐L1 with Fus‐CVs significantly increases the phago...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Angewandte Chemie 2021-12, Vol.133 (50), p.26524-26530
Hauptverfasser:	Meng, Qian‐Fang, Zhao, Yuyue, Dong, Chunbo, Liu, Lujie, Pan, Yuanwei, Lai, Jialin, Liu, Zhida, Yu, Guang‐Tao, Chen, Xiaoyuan, Rao, Lang
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigen presentation Antigens Cancer Cancer immunotherapy Carcinoma CD47/SIRPα cell membrane nanoparticle Chemistry Genetic engineering Immune checkpoint immune checkpoint therapy Immunity Immunotherapy Macrophages Mammary gland Melanoma Metastases PD-1/PD-L1 PD-L1 protein Phagocytosis Protein engineering Side effects Tumor cells Vesicle fusion Vesicles
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!